Sertindole for schizophrenia

Lewis, Robert; Bagnall, Anne‐Marie; Leitner, Maria

doi:10.1002/14651858.cd001715.pub2

Cited by 29 publications

(9 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast, there may be higher risks for dizziness, sedation, weight gain, substantial increases in serum prolactin, and tachycardia for individual second-generation antipsychotics 44–48,69. However, there has not been any systematic work or classification to categorize or distinguish the risks of these adverse effects between antipsychotics, particularly the second-generation antipsychotics.…”

Section: Safety and Tolerability Of Antipsychoticsmentioning

confidence: 99%

Current approaches to treatments for schizophrenia spectrum disorders, part I: an overview and medical treatments

Chien¹,

Yip²

2013

NDT

View full text Add to dashboard Cite

During the last three decades, an increasing understanding of the etiology, psychopathology, and clinical manifestations of schizophrenia spectrum disorders, in addition to the introduction of second-generation antipsychotics, has optimized the potential for recovery from the illness. Continued development of various models of psychosocial intervention promotes the goal of schizophrenia treatment from one of symptom control and social adaptation to an optimal restoration of functioning and/or recovery. However, it is still questionable whether these new treatment approaches can address the patients’ needs for treatment and services and contribute to better patient outcomes. This article provides an overview of different treatment approaches currently used in schizophrenia spectrum disorders to address complex health problems and a wide range of abnormalities and impairments resulting from the illness. There are different treatment strategies and targets for patients at different stages of the illness, ranging from prophylactic antipsychotics and cognitive–behavioral therapy in the premorbid stage to various psychosocial interventions in addition to antipsychotics for relapse prevention and rehabilitation in the later stages of the illness. The use of antipsychotics alone as the main treatment modality may be limited not only in being unable to tackle the frequently occurring negative symptoms and cognitive impairments but also in producing a wide variety of adverse effects to the body or organ functioning. Because of varied pharmacokinetics and treatment responsiveness across agents, the medication regimen should be determined on an individual basis to ensure an optimal effect in its long-term use. This review also highlights that the recent practice guidelines and standards have recommended that a combination of treatment modalities be adopted to meet the complex health needs of people with schizophrenia spectrum disorders. In view of the heterogeneity of the risk factors and the illness progression of individual patients, the use of multifaceted illness management programs consisting of different combinations of physical, psychological, and social interventions might be efficient and effective in improving recovery.

show abstract

Section: Safety and Tolerability Of Antipsychoticsmentioning

confidence: 99%

Current approaches to treatments for schizophrenia spectrum disorders, part I: an overview and medical treatments

Chien¹,

Yip²

2013

NDT

View full text Add to dashboard Cite

show abstract

“…The long-term haloperidol-controlled trial substantiated the favorable safety profile of sertindole, as a significantly lower incidence of akathisia (14% vs 24%), tremor (9% vs 21%), and hypertonia (9% vs 18%) was reported in patients treated with sertindole (24 mg/day) compared with those treated with haloperidol (10 mg/day). 48 Lewis et al, 69 in their meta-analysis of two haloperidol-controlled trials, 46 , 48 noted that the incidence of movement disorders was less frequent with sertindole (24 mg/day) than with haloperidol (10 mg/day), and not significantly different from placebo. Regarding risk ratio, sertindole 24 mg/day had a statistically significant lower risk than haloperidol 10 mg/day of akathisia (relative risk 0.47; P = 0.0004), hypertonia (0.45; P = 0.003), and tremor (0.36; P = 0.00009).…”

Section: Safety and Tolerabilitymentioning

confidence: 99%

“…In the placebo-controlled clinical trials, there was a statistically significant greater mean weight gain among participants taking sertindole (20 mg, mean weight gain of 3.3 kg) as compared to placebo (mean weight gain of 0.8 kg; P < 0.05). 69 …”

Section: Safety and Tolerabilitymentioning

confidence: 99%

Emerging treatments in the management of schizophrenia – focus on sertindole

Muscatello

Bruno²,

Pandolfo³

et al. 2010

DDDT

View full text Add to dashboard Cite

The antipsychotic treatment of schizophrenia is still marked by poor compliance, and drug discontinuation; the development of more effective and safer drugs still remains a challenge. Sertindole is a second-generation antipsychotic with high affinity for dopamine D2, serotonin 5-HT2A, 5-HT2C, and α1-adrenergic receptors, and low affinity for other receptors. Sertindole undergoes extensive hepatic metabolism by the cytochrome P450 isoenzymes CYP2D6 and CYP3A4 and has an elimination half-life of approximately three days. In controlled clinical trials sertindole was more effective than placebo in reducing positive and negative symptoms, whereas it was as effective as haloperidol and risperidone against the positive symptoms of schizophrenia. The effective dose-range of sertindole is 12–20 mg, administered orally once daily. The most common adverse events are headhache, insomnia, rhinitis/nasal congestion, male sexual dysfunction, and moderate weight gain, with few extrapyramidal symptoms and metabolic changes. Sertindole is associated with corrected QT interval prolongation, with subsequent risk of serious arrythmias. Due to cardiovascular safety concerns, sertindole is available as a second-line choice for patients intolerant to at least one other antipsychotic agent. Further clinical studies, mainly direct “head-to-head” comparisons with other second-generation antipsychotic agents, are needed to define the role of sertindole in the treatment of schizophrenia.

show abstract

“…Sertindole is a phenylindole derivative (1-[2-[4-[5-chloro-1-(4-fluorophenyl)-1H-indol-3yl]-1-piperidinyl] ethyl-2-imidazolidi-none) which is manufactured by Lundbeck Ltd and is sold as Serdolect or Serlect (in several European countries) in 4 mg, 12 mg, 16 mg and 20 mg tablets. It is a long acting 5-HT2 / alpha1 antagonist and a very mild D2 antagonist (Lewis 2005). Sertindole may cause QT-prolongation and ventricular tachycardia more than some other atypical antipsychotics.…”

Section: How the Intervention Might Workmentioning

confidence: 99%

Sertindole versus other atypical antipsychotics for schizophrenia

Komossa¹,

Rummel‐Kluge²,

Hunger³

et al. 2007

Cochrane Database of Systematic Reviews

Self Cite

View full text Add to dashboard Cite

Background-In many countries of the industrialised world second generation (atypical) antipsychotics have become the first line drug treatment for people with schizophrenia. The question as to whether and, if so, how much the effects of the various second generation antipsychotics differ is a matter of debate. Objectives-To evaluate the effects of sertindole compared with other second generation antipsychotics for people with schizophrenia and schizophrenia-like psychosis.

show abstract

Sertindole for schizophrenia

Abstract: Simpson Angus Scale-SAS (Simpson 1970) This ten-item scale with a scoring system of 0-4 for each item, measures drug-induced parkinsonism, a short-term drug-Sertindole for schizophrenia (Review)

Cited by 29 publications

References 59 publications

Current approaches to treatments for schizophrenia spectrum disorders, part I: an overview and medical treatments

Current approaches to treatments for schizophrenia spectrum disorders, part I: an overview and medical treatments

Emerging treatments in the management of schizophrenia – focus on sertindole

Sertindole versus other atypical antipsychotics for schizophrenia

Contact Info

Product

Resources

About

Sertindole for schizophrenia

Abstract: Simpson Angus Scale-SAS (Simpson 1970) This ten-item scale with a scoring system of 0-4 for each item, measures drug-induced parkinsonism, a short-term drug-Sertindole for schizophrenia (Review)

Cited by 29 publications

References 59 publications

Current approaches to treatments for schizophrenia spectrum disorders, part I: an overview and medical treatments

Current approaches to treatments for schizophrenia spectrum disorders, part I: an overview and medical treatments

Emerging treatments in the management of schizophrenia &ndash; focus on sertindole

Sertindole versus other atypical antipsychotics for schizophrenia

Contact Info

Product

Resources

About

Emerging treatments in the management of schizophrenia – focus on sertindole